GlassScriptPhysician profile
Julie L Hung
NPI 1124053863
$15,945.82
in general payments reported to CMS, 2019-2025
57 companies · $2,569 in 2025
The $2,569 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $1,271 · 2021: $2,355 · 2022: $2,450 · 2023: $3,214 · 2024: $2,777 · 2025: $2,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,551 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,551.30 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,882.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,350.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,127.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $953.99 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $927.76 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $853.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $760.17 | 2019-2025 | Gardasil 9, Belsomra, Steglatro |
| Amgen INC. | $595.31 | 2019-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $552.24 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.55 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $475.93 | 2019-2025 | |
| Abbott Laboratories | $474.98 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $400.74 | 2019-2025 | Xifaxan, Trulance |
| Ibsa Pharma INC. | $323.57 | 2019-2025 | Licart, Tirosint, Flector |
| Shield Therapeutics INC | $289.34 | 2022-2025 | Accrufer |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Hung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.